NCT02217826View on ClinicalTrials.gov

Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

Not specified

Primary Completion Date

April 30, 2014

Conditions
Healthy
Interventions
DRUG

DG3173

DRUG

Saline

DRUG

Octreotide

Sponsors
All Listed Sponsors
lead

Aspireo Pharmaceuticals Limited

INDUSTRY